NASOPHARYNGEAL NONKERATINIZING CARCINOMA

Clinical trials for NASOPHARYNGEAL NONKERATINIZING CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new NASOPHARYNGEAL NONKERATINIZING CARCINOMA trials appear

Sign up with your email to follow new studies for NASOPHARYNGEAL NONKERATINIZING CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Immunotherapy boost tested for Tough-to-Treat head & neck cancer

Disease control Terminated

This study tested whether adding an immunotherapy drug called nivolumab to standard chemotherapy could help people with advanced nasopharyngeal cancer that has come back or spread. It aimed to see if the combination helped patients live longer or better control the cancer compare…

Matched conditions: NASOPHARYNGEAL NONKERATINIZING CARCINOMA

Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 25, 2026 14:09 UTC

NASOPHARYNGEAL NONKERATINIZING CARCINOMA

Get alerted when new NASOPHARYNGEAL NONKERATINIZING CARCINOMA trials appear

Immunotherapy boost tested for Tough-to-Treat head & neck cancer